Abzena Signs Protein Engineering Agreement with NYU Langone Health

Abzena plc has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering and drug discovery services, will help NYU Langone’s drug discovery accelerator, the Office of Therapeutics Alliances (OTA), to develop novel biopharmaceutical therapeutics.

The first project under this master agreement centres around the development of a novel biopharmaceutical being developed by NYU OTA for the treatment of severe autoimmune disease. Abzena will provide integrated development support from its bioassay, immunology and protein engineering groups.

NYU School of Medicine is one of the USA’s top-ranked medical schools. An integral part of NYU Langone Health, the School of Medicine at its core is committed to improving the human condition through medical education, scientific research, and direct patient care.

Dr. Campbell Bunce, SVP, Scientific Operations, Abzena commented:

“It’s fantastic that our expertise and integrated offering across our biology group is being used in the development of another promising treatment.

“This agreement represents another example of Abzena supporting exciting drug candidates from academic groups, utilising not just our services but also our significant biologics know-how.”

Dr. Nadim Shohdy, Assistant Dean and Director, Therapeutics Alliances, NYU Langone commented:

“We are very excited to execute both the master agreement, and to launch this inaugural project with Abzena.

“This partnership will augment NYU Langone’s access to deep biologics capabilities and expertise to further enhance OTA’s mission to translate the research of our faculty into therapeutic products that help patients.”